BMS will collaborate with Janssen on a novel cardiovascular therapy

| By | Bristol-Myers Squibb, Drug Development, Janssen
0
325

Bristol-Myers Squibb announced a worldwide collaboration with Janssen Pharmaceuticals on a Factor XIa (FXIa) inhibitor program that includes the development and commercialization of Bristol-Myers Squibb’s Factor XIa (FXIa) inhibitor, BMS-986177, an investigational anticoagulant compound being studied for prevention and treatment of major thrombotic conditions.

Thrombotic disorders include cardiovascular conditions such as coronary artery disease, stroke and peripheral artery disease. BMS-986177 is an inhibitor of Factor XIa, and is being explored for its potential to improve upon the standard of care by reducing the risk of vascular events – without increasing the risk of bleeding – in patients with thrombotic disorders.

The companies are expected to advance BMS-986177 into Phase 2 clinical trials in the second half of 2018 for the study of secondary stroke prevention.

Bristol-Myers Squibb has a strong heritage of pioneering research and advancing the development of novel compounds to address areas of high unmet need for patients with serious cardiovascular conditions. The collaboration will leverage both companies’ resources and expertise to establish a broad development program across multiple indications.